<DOC>
	<DOCNO>NCT02007291</DOCNO>
	<brief_summary>Life expectancy Brazil increase markedly last 30 year . Hence , age-related disorder , Alzheimer 's disease ( AD ) , warrant special attention due high prevalence elderly . Pharmacologic treatment AD base cholinesterase inhibitor ( ChEI ) memantine , lead modest clinical benefit short long-term . However , clinical response heterogeneous need investigation . Objective : To investigate rate response ChEI AD three month treatment . Methods : Patients mild moderate dementia due probable AD AD associate cerebrovascular disease include study .</brief_summary>
	<brief_title>Good Rate Clinical Response Cholinesterase Inhibitors Alzheimer 's Disease After Three Months Treatment</brief_title>
	<detailed_description>The subject assess baseline three month ChEI treatment . Subjects submit Mini-Mental State Examination ( MMSE ) , Mattis Dementia Rating Scale , Katz Basic Activities Daily Living , Pfeffer Functional Activities Questionnaire , Neuropsychiatric Inventory Cornell Scale Depression Dementia . Good response define gain ≥2 point MMSE three month treatment relation baseline .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Patients fulfil National Institute Aging Alzheimer 's Association diagnostic criterion probable AD dementia NINDSAIREN ( National Institute Neurological Disorders Stroke Association Internationale pour la Recherché et l'Enseignement en Neurosciences ) diagnostic criterion AD cerebrovascular disease ( AD + CVD ) Patients present mild moderate dementia accord Clinical Dementia Rating ( CDR ) , i.e. , CDR 1 2 , respectively Patients treat ChEI memantine study entry Patients diagnose frontotemporal dementia , dementia Lewy body vascular dementia , Patients CDR 3 Illiterate patient Patients different comorbidities , sign clinical decompensation</criteria>
	<gender>All</gender>
	<minimum_age>59 Years</minimum_age>
	<maximum_age>93 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Alzheimer , MMSE , response , colinesterase inhibitor ( ChEI )</keyword>
</DOC>